IZBrunch – Science meets Science
The IZBrunch is a networking event in which the managing directors of the IZB start-ups and the stakeholders of the Campus Martinsried/Großhadern exchange ideas in an informal atmosphere. This event usually takes place on the last Thursday of the month at the Faculty Club G2B (Gateway to Biotech), which is located in the heart of the Martinsried Campus on the grounds of the Biotechnology Innovation and Start-up Center.
At each event, a professor from a campus institute or a director from the Max Planck Institutes of Biochemistry/Neurobiology and an IZB start-up present their respective research. After the lectures, guests have the opportunity to discuss the topic in more detail with the speaker during a business lunch. Thus, the IZBrunch has established itself in recent years as a very popular networking event on campus.
Due to the space and the currently valid corona rules, the event is limited to 30 people. Prior registration is absolutely necessary. Please send it to the following email address: ed.enilno-bzi@bzi
Save the Date: Next IZBrunch on November 18, 2021
Speakers
Dr. Simone Moser
Group Leader Pharmaceutical Biology,
Center for Drug Research, Ludwig-Maximilians-University
Theme: From waste to resource – chlorophyll breakdown as source of bioactive compounds
Phyllobilins are formed upon chlorophyll degradation, and have been regarded as waste products of a detoxification process for a long time. A change of this paradigm, however, is long overdue. We reveal important pharmacological activities of phyllobilins and set the stage to investigate their roles as ingredients of herbal medicines and food.
Dr. Sebastian Mangold
Managing Director mk2 Biotechnologies
Theme: Enabling peptides for mass application
mk2 Biotechnologies developed a novel peptide synthesis platform that enables the production of peptides on large scales and low cost while still fulfilling all the technical requirements. Customers can for the first time access required amounts of affordable peptides for applications in mass segments.
Welcome & Moderation
Dr. Peter Hanns Zobel
Managing Director of the IZB
Theme:
News of the IZB
Archive: IZBrunch on October 21, 2021
The speakers
Prof. Nadia Harbeck
Head of the Breast Center of the University of Munich (Comprehensive Cancer Center CCC LMU), Head of interdisciplinary tumor board for breast cancer, Professor for Conservative Oncology at the Ludwig-Maximilians-University (LMU)
Topic: Opportunities and risks of integrating eHealth into oncology therapy management
Oral therapies are becoming increasingly common in oncology and require interprofessional patient management, with close communication with the care team critical to treatment success. eHealth Support improves treatment adherence, patient satisfaction, and prognosis. New legislation now enables the prescription of digital health applications (DIGAs) in Germany. The interactive eHealth application CANAKDO is being used and further developed in the care of breast cancer patients in everyday clinical practice and in studies.
Dr. Jens Ruhe
CEO SciRhom GmbH
Topic: Targeting iRhom2 – a new paradigm for the treatment of autoimmune diseases
SciRhom develops first-in-class therapeutic antibodies against iRhom2, As a key regulator of TACE, iRhom2 activates several pro-inflammatory pathways, including TNF-alpha signaling. Our antibodies allow to simultaneously block these disease-causing pathways, promising significant improvement over current autoimmune therapies.
Welcome & Moderation
Dr. Peter Hanns Zobel
Managing Director, IZB
Topic:
News from the IZB
Archive: IZBrunch from September 23, 2021
Speaker
Prof. Dr. Olivia Merkel
Department of Pharmacy, LMU Munich
Theme: Inhalation therapy and prevention of respiratory virus infections with siRNA
The COVID19 pandemic has highlighted that we need better antiviral therapies, especially for respiratory viral diseases. We have developed inhalation therapies consisting of siRNA nanoparticles which inhibit
the viral genome of coronaviruses. The advantage over vaccination is the therapeutic index for virus variants and new coronaviruses.
Ulrich Scherbel
Managing Director AMSilk GmbH
Theme: Shaping the future with silk proteins for products in various industries
AMSilk GmbH is the leading company in the world to produce silk biopolymers using biotechnological processes on an industrial scale, which have all the functional properties of natural silk. The silk biopolymers are sold in the form of suspensions, hydrogel,powder or as fibers. In addition to its use in the coating of medical technology products and in the apparel industry, exciting new markets are being developed.
Welcome/Moderation
Dr. Peter Hanns Zobel
Managing Director of the IZB
Theme:
News of the IZB
Who attends?
Faculty Club members, directors and research group leaders of the Max Planck Institutes, LMU professors, managing directors and board members of the IZB companies, and executives of the Martinsried/Großhadern campus.
Registration for the IZBrunch
